Art

J-GLOBAL ID：201902211174205752   Reference number：19S1350979

Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: Results from ASCEND-2

Author (16)： Crinò, Lucio (University Medical, School of Perugia, Azienda Ospedale Perugia) ,  De Marinis, Filippo (European Institute of Oncology) ,  Scagliotti, Giorgio (University of Torino) ,  Ahn, Myung-Ju (Sungkyunkwan University, School of Medicine, Samsung Medical Center) ,  Groen, Harry J. M. (University of Groningen, University Medical Center Groningen) ,  Wakelee, Heather (Stanford University, Medical Center) ,  Hida, Toyoaki (Aichi Cancer Center) ,  Nishio, Makoto (Japanese Foundation for Cancer Research) ,  Mok, Tony (Chinese University of Hong Kong) ,  Spigel, David (Sarah Cannon Research Institute) ,  Felip, Enriqueta (Vall d'Hebron University) ,  Branle, Fabrice (Novartis Pharma AG) ,  Quadrigli, Massimiliano (Novartis Pharma AG) ,  Emeremni, Chetachi (Novartis Pharma) ,  Zhang, Jie (Novartis Pharma) ,  Shaw, Alice T. (Massachusetts General Hospital)
Material： Journal of Clinical Oncology
Volume： 34  Issue： 24  Page： 2866-2873  Publication year： 2016 
JST Material Number： SCOPUS  ISSN： 0732-183X  CODEN： JCOND 
Country of issue： United States (USA)  Language： English (EN)

Terms in the title (1)： Cancer